New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicinesSilo ...

The hype surrounding the psychedelic drug ibogaine reached a fever pitch in April, when President Donald Trump talked up its ...

The Trump administration doesn't plan to reclassify the drug for medical use at this time — it will remain a Schedule I drug.

Traumatic experiences can cause memory problems, and estrogen may be a key factor that shapes the brain's resilience against ...

Veterans are again on the front lines of an advance in medicine — this time involving psychedelics — as they search for ways ...

Today, veterans are once again on the frontlines of an advance in medicine — this time involving psychedelics — as they search for ways to address the invisible wounds of war: post-traumatic stress, ...

A new study suggests accelerated TMS therapy may help repair stress-damaged brain circuits, offering faster relief and new ...

The hype surrounding psychedelic drug ibogaine reached a fever pitch earlier this month when President Donald Trump talked up its potential at a White House event promoting increased access to ...

After decades of backing a “war on drugs,” the GOP has warmed to psychedelics for mental health treatment as high-profile ...